Teva Pharmaceutical Industries Limited · TASE:TEVA
Teva Pharmaceutical Industries — Corporate Update (October 2026)
15 slides from Teva Pharmaceutical Industries's corporate update, Oct 9, 2026
Slide 1: WELTRUZA (olanzapine) Approval Call
WE LT RUZA’ (olanzapine) resseeeers, C 318mg ) (425mg ) (531mg ) October 9, 2026
Slide 2: Forward-looking statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our futu
Slide 3: Introduction, WELTRUZA Approval, Q&A
1 Introduction President and Chief Executive Officer 2 WELTRUZA Approval EVP, Global R&D & Chief Medical Officer 3 Q&A EVP, US Commercial Officer EVP, Chief Financial Officer 3|
Slide 4: President and Chief Executive Officer
President and Chief Executive Officer 4|
Slide 5: Pivot to Growth: growth engines, innovation, generics, focus
Deliver on Step up Sustain generics Focus our growth engines innovation powerhouse business 5|
Slide 6: Key anticipated milestones for 2026
Assets Key anticipated milestone for 2026 Timing duvakitug UC/CD Phase 2 maintenance data H1’26 ecopipam NDA accepted by the FDA with priority review H1’26 Vitiligo Phase 1b topline results H1'26 Anti-IL-15 Celiac Phase 2a topline results H2'26 DARI Targeted completion of pivotal Phase 3 studies H2'
Slide 7: Executive Vice President, Global R&D & Chief Medical Officer
Executive Vice President, Global R&D & Chief Medical Officer 7|
Slide 8: Course of illness over time in schizophrenia
Premorbid Prodromal phase Progressive phase Chronic phase phase Functional impairment Acute exacerbations Remission Negative symptoms Relapse drives Disability progression Cognitive deficits Illness severity Relapse 80% experience multiple 1st psychotic Positive symptoms relapses in first 5 years ep
Slide 9: Significant U.S. market opportunity
Significant U.S. market opportunity Requirements to increase LAI penetration ~2.2M1 Deep understanding of Diagnosed patients in the US in 2026 the patient journey Demonstrated safety ~1.5M2 profile Patients treated with oral antipsychotics Go-to-market ~20%2 capabilities oral olanzapine 9| 1. DRG /
Slide 10: Addressing unmet medical need with proven science at high velocity
Unmet Patient Differentiated High-Velocity On-Target Right First Needs By Design Execution Submission Time Approval Addressing unmet medical need with proven science at high velocity 10 |
Slide 11: Proven efficacy of olanzapine, monthly subcutaneous LAI
Monthly Subcutaneous PROVEN Long-Acting Injection EFFICACY OF • NO loading dose OLANZAPINE • NO oral supplementation • NO post-injection monitoring • Filling a long-standing gap in care 11 |
Slide 12: Relapse after stabilization (SOLARIS Period 2)
Relapse after stabilization (SOLARIS Period 2) Period 2: open-label, up to 48 weeks 6% 1% 5% 4% n=10 Wk 0 Wk 56 100 56% of participants stabilized on WELTRUZA Stabilized participants, % 80 60 94% 99% 95% 96% n=221 4% of stabilized participants relapsed 40 20 21% achieved remission after ≥6 months 0
Slide 13: Teva
teva
Slide 14: SOLARIS data webcast, presentation and prescribing information
WELTRUZA Phase 3 SOLARIS Data Webcast WELTRUZA Phase 3 SOLARIS Data Presentation U.S. Prescribing Information 14 |
Slide 15: We are all in for better health
v We are all in for better health
Teva Pharmaceutical Industries — Corporate Update (October 2026) on 6ix